EirGenix, Inc.

About EirGenix, Inc.

EirGenix is a global biologics CDMO and biosimilar developer delivering high quality, cost competitive solutions from early development through commercial manufacturing. Founded in 2012, we support pharmaceutical and biotechnology partners worldwide with fully integrated services spanning cell line development, process development, analytical testing, cGMP manufacturing, and ADC development. With expertise in both mammalian and microbial systems, EirGenix provides flexible, scalable, and regulatory ready capabilities designed to accelerate development timelines and ensure reliable global supply. With two state of the art facilities in Taiwan and a growing presence in Europe, EirGenix enables pharmaceutical partners worldwide to accelerate development, reduce cost of goods, and reliably supply biologics for global markets. Our integrated biologics platform supports a broad range of modalities, including monoclonal antibodies, bispecific antibodies, recombinant proteins, fusion proteins, and antibody-drug conjugates (ADCs). Leveraging proprietary expression technologies, robust process development, analytical expertise, and cGMP manufacturing capabilities, we help clients efficiently advance programs from development through commercialization. In addition to CDMO services, EirGenix is also a biosimilar developer with successful experience in product development, regulatory approval, and commercialization. Through flexible partnership models including CDMO, co-development, and licensing, we combine scientific expertise, manufacturing excellence, and global regulatory experience to help partners bring innovative biologics to patients worldwide.